NextSource Biotechnology Announces FDA Short Supply Release of the Formally Known Bristol Myers Squibb (CeeNu) Brand Oncology Product Now Currently Marketed Under the NextSource Biotechnology Lomustine (CCNU) Exclusively in the U.S.